Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2026 02:15 ET | Source: Basilea Pharmaceutica International Ltd, Allschwil

Basilea announces start of first‑in‑human study of novel antibiotic BAL2420

Allschwil, Switzerland, March 23, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial...
March 20, 2026 13:34 ET | Source: Genco Shipping & Trading Limited

Genco Shipping & Trading Issues Statement

NEW YORK, March 20, 2026 (GLOBE NEWSWIRE) -- Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the global...
March 20, 2026 08:00 ET | Source: ABI Research

Security IP Market Accelerates as OEM Demand for Integrated, Certification-Ready Components Surges

NEW YORK, March 20, 2026 (GLOBE NEWSWIRE) -- Security IP is entering a new phase of accelerated growth as OEMs push for fully integrated, certification‑ready security components across semiconductor...
March 19, 2026 12:45 ET | Source: Cosmos Health Inc.

Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions

Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results
March 19, 2026 08:00 ET | Source: Genco Shipping & Trading Limited

Genco Shipping & Trading Rejects Revised, Non-Binding Indicative Proposal from Diana Shipping Inc.

Proposal Substantially Undervalues Genco, Fails to Provide an Appropriate Premium and Presents Execution Risks “Fire Sale” of 16 Genco Vessels to a Competitor Highlights Diana’s Undervalued Proposal...
March 19, 2026 02:00 ET | Source: Molecular Partners

Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes

Highly comparable biodistribution profiles of Radio-DARPin candidates labeled with imaging isotopes 177Lu or 203Pb allows for rapid expansion of pipeline with multiple therapeutic isotopes ...
March 18, 2026 12:45 ET | Source: TOUAX

Touax: Results 2025

PRESS RELEASE Paris, 18 March 2026 – 5:45pm YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION 2025 RESULTS Positive net income in an unstable geopolitical and economic...
March 18, 2026 06:05 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in...
March 18, 2026 06:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Proceeds expected to support expansion of next-generation GABA-aminotransferase inhibitor, OV329, into tuberous sclerosis complex and infantile spasmsFinancing led by Point72 with participation from...
March 17, 2026 16:30 ET | Source: Molecular Partners

Molecular Partners to Hold Three Poster Presentations at AACR 2026

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of...